Epidemiology and clinical severity of the serotypes of human parainfluenza virus in children with acute respiratory infection.
Acute respiratory infection
Children
Human parainfluenza virus
Serotypes
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
26 10 2023
26 10 2023
Historique:
received:
23
12
2022
accepted:
18
10
2023
medline:
30
10
2023
pubmed:
27
10
2023
entrez:
26
10
2023
Statut:
epublish
Résumé
Acute respiratory infections (ARI) are a threat to human health and survival, resulting in many paediatric hospitalisations. However, the epidemiological and clinical severity characteristics of the human parainfluenza virus (PIV), one of the most prevalent respiratory viruses, are not well understood in children. To identify the epidemiological features of PIV infection, in 2019, hospitalised children with ARI were screened using multiplex polymerase chain reaction (PCR) for PIV and 10 other common respiratory pathogens. Subtyping of randomly selected PIV-positive samples was performed using reverse transcription-PCR. Demographics, epidemiology, clinical manifestations, diagnosis, and outcomes were compared between PIV subtypes. The annual detection rate for PIV was 14.9%, with a peak from April to September. Children under one year of age had the highest rate of PIV infection (45.5%) compared to other age groups. Of the 121 sequenced samples, 58.7%, 36.4% and 4.9% were positive for PIV-3, PIV-1 and PIV-2, respectively, and no PIV-4 was detected. Severe infections were associated with pre-existing underlying diseases and co-infections, but not with PIV serotype. After excluding cases of co-infection, we found that PIV-2 infection was associated with upper respiratory tract infections, whereas PIV-1 and PIV-3 mainly caused lower respiratory tract infections. Apart from the proportion of patients with fever, there were no significant differences among the three subtypes in terms of clinical symptoms, severity, and outcome. Here, PIV was the main pathogen causing ARI in hospitalised children. Appropriate attention should be paid to children with underlying diseases and co-infections to prevent the worsening of severe PIV infection.
Sections du résumé
BACKGROUND
Acute respiratory infections (ARI) are a threat to human health and survival, resulting in many paediatric hospitalisations. However, the epidemiological and clinical severity characteristics of the human parainfluenza virus (PIV), one of the most prevalent respiratory viruses, are not well understood in children.
METHODS
To identify the epidemiological features of PIV infection, in 2019, hospitalised children with ARI were screened using multiplex polymerase chain reaction (PCR) for PIV and 10 other common respiratory pathogens. Subtyping of randomly selected PIV-positive samples was performed using reverse transcription-PCR. Demographics, epidemiology, clinical manifestations, diagnosis, and outcomes were compared between PIV subtypes.
RESULTS
The annual detection rate for PIV was 14.9%, with a peak from April to September. Children under one year of age had the highest rate of PIV infection (45.5%) compared to other age groups. Of the 121 sequenced samples, 58.7%, 36.4% and 4.9% were positive for PIV-3, PIV-1 and PIV-2, respectively, and no PIV-4 was detected. Severe infections were associated with pre-existing underlying diseases and co-infections, but not with PIV serotype. After excluding cases of co-infection, we found that PIV-2 infection was associated with upper respiratory tract infections, whereas PIV-1 and PIV-3 mainly caused lower respiratory tract infections. Apart from the proportion of patients with fever, there were no significant differences among the three subtypes in terms of clinical symptoms, severity, and outcome.
CONCLUSION
Here, PIV was the main pathogen causing ARI in hospitalised children. Appropriate attention should be paid to children with underlying diseases and co-infections to prevent the worsening of severe PIV infection.
Identifiants
pubmed: 37885007
doi: 10.1186/s12985-023-02214-9
pii: 10.1186/s12985-023-02214-9
pmc: PMC10604402
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
245Informations de copyright
© 2023. The Author(s).
Références
Clin Infect Dis. 2006 Oct 15;43(8):1016-22
pubmed: 16983614
Pediatr Int. 2020 Jan;62(1):52-58
pubmed: 31705838
Clin Microbiol Rev. 2003 Apr;16(2):242-64
pubmed: 12692097
J Pediatr (Rio J). 2018 Sep - Oct;94(5):554-558
pubmed: 28963878
Lancet. 2019 Aug 31;394(10200):757-779
pubmed: 31257127
MMWR Morb Mortal Wkly Rep. 2021 Jul 23;70(29):1013-1019
pubmed: 34292924
Curr Allergy Asthma Rep. 2017 Mar;17(3):16
pubmed: 28283855
J Am Geriatr Soc. 1998 Sep;46(9):1112-7
pubmed: 9736104
Pediatrics. 2013 Jul;132(1):28-36
pubmed: 23733801
Pediatr Infect Dis J. 2006 May;25(5):447-8
pubmed: 16645510
Epidemiol Infect. 2017 Apr;145(6):1210-1220
pubmed: 28095926
BMC Infect Dis. 2013 Jan 23;13:28
pubmed: 23343342
J Infect Dis. 1997 Apr;175(4):807-13
pubmed: 9086134
Clin Microbiol Rev. 2006 Jul;19(3):571-82
pubmed: 16847087
Virol J. 2019 Jun 24;16(1):84
pubmed: 31234918
Infect Drug Resist. 2012;5:121-7
pubmed: 22893749
J Pediatric Infect Dis Soc. 2016 Mar;5(1):7-13
pubmed: 26908486
BMC Infect Dis. 2011 Dec 14;11:345
pubmed: 22168387
Clin Infect Dis. 1997 Dec;25(6):1421-9
pubmed: 9431390
Pediatrics. 2006 Oct;118(4):1774-93
pubmed: 17015575
Virol J. 2022 Sep 6;19(1):141
pubmed: 36064562
Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S123-5
pubmed: 18820572
JAMA. 2000 Jan 26;283(4):499-505
pubmed: 10659876
BMC Infect Dis. 2021 Apr 7;21(1):323
pubmed: 33827449
Influenza Other Respir Viruses. 2014 Mar;8(2):217-27
pubmed: 24286248
Beginnings. 1994 Jan;14(1):2-3
pubmed: 8298256
J Clin Virol. 2020 Mar;124:104261
pubmed: 31954277
Virol Sin. 2021 Dec;36(6):1543-1553
pubmed: 34523109
Influenza Other Respir Viruses. 2017 Nov;11(6):564-568
pubmed: 29054112
J Pediatric Infect Dis Soc. 2012 Dec;1(4):314-28
pubmed: 26619424
Arch Pediatr Adolesc Med. 2000 Oct;154(10):997-1000
pubmed: 11030851